- Home
- WYHG vs ABOS Comparison
WYHG vs ABOS Comparison
Compare WYHG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- ABOS
- Stock Information
- Founded
- WYHG 1915
- ABOS 1996
- Country
- WYHG China
- ABOS United States
- Employees
- WYHG N/A
- ABOS N/A
- Industry
- WYHG
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- WYHG
- ABOS Health Care
- Exchange
- WYHG NYSE
- ABOS Nasdaq
- Market Cap
- WYHG 77.0M
- ABOS 72.7M
- IPO Year
- WYHG 2024
- ABOS 2021
- Fundamental
- Price
- WYHG $1.25
- ABOS $1.46
- Analyst Decision
- WYHG
- ABOS Strong Buy
- Analyst Count
- WYHG 0
- ABOS 4
- Target Price
- WYHG N/A
- ABOS $6.50
- AVG Volume (30 Days)
- WYHG 208.4K
- ABOS 622.3K
- Earning Date
- WYHG 08-15-2025
- ABOS 08-12-2025
- Dividend Yield
- WYHG N/A
- ABOS N/A
- EPS Growth
- WYHG N/A
- ABOS N/A
- EPS
- WYHG 0.20
- ABOS N/A
- Revenue
- WYHG $147,996,867.00
- ABOS N/A
- Revenue This Year
- WYHG N/A
- ABOS N/A
- Revenue Next Year
- WYHG N/A
- ABOS N/A
- P/E Ratio
- WYHG $4.84
- ABOS N/A
- Revenue Growth
- WYHG 19.02
- ABOS N/A
- 52 Week Low
- WYHG $1.10
- ABOS $0.86
- 52 Week High
- WYHG $12.00
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- ABOS 58.51
- Support Level
- WYHG N/A
- ABOS $1.12
- Resistance Level
- WYHG N/A
- ABOS $1.27
- Average True Range (ATR)
- WYHG 0.00
- ABOS 0.06
- MACD
- WYHG 0.00
- ABOS 0.00
- Stochastic Oscillator
- WYHG 0.00
- ABOS 77.78
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The main categories of products are cured meat products, including cured pork sausages, cured pork meat and other cured meat products, such as cured chicken, cured duck and cured fish; snack products, including ready-to-eat sausages, jerky, duck necks, duck feet and claypot rice; and frozen meat products, including frozen sausages, frozen beef patties and frozen chicken breast fillets.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.